Genetic Testing

Low Use of Genomic Tests Among Oncologists for Lung and Colorectal Cancers

Laura Morgan

August 2017, Vol 7, No 8 - Genetic Testing

The introduction of targeted cancer drugs has revolutionized cancer treatment, especially in patients with colorectal cancer (CRC) or non–small-cell lung cancer (NSCLC). These drugs have been accompanied by genomic assays that test for certain mutations, such as ALK, KRAS, BRAF, or EGFR, which often help guide cancer treatment decisions by identifying patients who would benefit most from certain therapies over others. However, there are few data regarding the real-world use of genomic tests among oncologists for these cancers. [ Read More ]